Advertisement

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

Peter Clark, MA, MD, FRCP: A Payer Perspective

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Advertisement

Advertisement

Nov

02

Today In Oncology

OptiTROP-Lung06 A Potential Alternative to Chemotherapy in Advanced PD-L1–Negative NSCLC?

How Medicare Advantage and Traditional Medicare Influence Palliative and Hospice Care Implementation

Selpercatinib Sacituzumab Govitecan Show Activity in Thyroid Cancer Subtypes

ASTRO Updates Guideline on Shorter-Course Radiation Therapy for Localized Prostate Cancer

High-Risk Melanoma Personalized mRNA Vaccine Plus Immunotherapy Reduces Risk of Recurrence After Surgery

Advertisement

© 2026 HSP News Service, L.L.C.